Clinical, histopathological, and dermatoscopic characterization of eruptive pseudoangioma developing after COVID‐19 vaccination—A case‐series.

Past history of COVID-19 infection was present in 4 patients (2-3 months back), while 3 patients had a history of dengue infection before vaccination. Clinical, histopathological, and dermatoscopic characterization of eruptive pseudoangioma developing after COVID-19 vaccination - A case-series Keywords: COVID-19; COVID-19 vaccine; eruptive pseudoangioma; eruptive pseudoangiomatosis; SARS-CoV-2 EN COVID-19 COVID-19 vaccine eruptive pseudoangioma eruptive pseudoangiomatosis SARS-CoV-2 1799 1801 3 05/24/22 20220501 NES 220501 ETHICS APPROVAL Due ethical approval was taken from institutional ethics committee. [Extracted from the article]